Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability.

Kategaya L, Perumal SK, Hager JH, Belmont LD.

iScience. 2019 Mar 29;13:488-497. doi: 10.1016/j.isci.2019.02.006. Epub 2019 Mar 18.

2.

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, Lubach JW, McKenzie BS, Ortwine DF, Schutt L, Tay S, Wei B, Reif K, Liu L, Wong H, Young WB.

J Med Chem. 2018 Mar 22;61(6):2227-2245. doi: 10.1021/acs.jmedchem.7b01712. Epub 2018 Feb 23.

PMID:
29457982
3.

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

Johnson AR, Kohli PB, Katewa A, Gogol E, Belmont LD, Choy R, Penuel E, Burton L, Eigenbrot C, Yu C, Ortwine DF, Bowman K, Franke Y, Tam C, Estevez A, Mortara K, Wu J, Li H, Lin M, Bergeron P, Crawford JJ, Young WB.

ACS Chem Biol. 2016 Oct 21;11(10):2897-2907. Epub 2016 Sep 7.

PMID:
27571029
4.

Cell biology and the "real world".

Blackstone C, Belmont LD.

Mol Biol Cell. 2016 Mar 15;27(6):878-9. doi: 10.1091/mbc.E15-11-0764. No abstract available.

5.

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, Young A, Mitten M, Ingalla E, Darbonne WC, Oleksijew A, Tapang P, Yue P, Oeh J, Lee L, Maiga S, Fairbrother WJ, Amiot M, Souers AJ, Sampath D.

Mol Cancer Ther. 2016 May;15(5):1132-44. doi: 10.1158/1535-7163.MCT-15-0730. Epub 2016 Mar 3.

6.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, Belmont LD, Nimmer P, Xiao Y, Ma XM, Lowes KN, Kovar P, Chen J, Jin S, Smith M, Xue J, Zhang H, Oleksijew A, Magoc TJ, Vaidya KS, Albert DH, Tarrant JM, La N, Wang L, Tao ZF, Wendt MD, Sampath D, Rosenberg SH, Tse C, Huang DC, Fairbrother WJ, Elmore SW, Souers AJ.

Sci Transl Med. 2015 Mar 18;7(279):279ra40. doi: 10.1126/scitranslmed.aaa4642.

PMID:
25787766
7.

Ubiquitination profiling identifies sensitivity factors for IAP antagonist treatment.

Varfolomeev E, Izrael-Tomasevic A, Yu K, Bustos D, Goncharov T, Belmont LD, Masselot A, Bakalarski CE, Kirkpatrick DS, Vucic D.

Biochem J. 2015 Feb 15;466(1):45-54. doi: 10.1042/BJ20141195.

PMID:
25423073
8.

Structural basis for resistance to diverse classes of NAMPT inhibitors.

Wang W, Elkins K, Oh A, Ho YC, Wu J, Li H, Xiao Y, Kwong M, Coons M, Brillantes B, Cheng E, Crocker L, Dragovich PS, Sampath D, Zheng X, Bair KW, O'Brien T, Belmont LD.

PLoS One. 2014 Oct 6;9(10):e109366. doi: 10.1371/journal.pone.0109366. eCollection 2014.

9.

Dependence of tumor cell lines and patient-derived tumors on the NAD salvage pathway renders them sensitive to NAMPT inhibition with GNE-618.

Xiao Y, Elkins K, Durieux JK, Lee L, Oeh J, Yang LX, Liang X, DelNagro C, Tremayne J, Kwong M, Liederer BM, Jackson PK, Belmont LD, Sampath D, O'Brien T.

Neoplasia. 2013 Oct;15(10):1151-60.

10.

Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.

Shames DS, Elkins K, Walter K, Holcomb T, Du P, Mohl D, Xiao Y, Pham T, Haverty PM, Liederer B, Liang X, Yauch RL, O'Brien T, Bourgon R, Koeppen H, Belmont LD.

Clin Cancer Res. 2013 Dec 15;19(24):6912-23. doi: 10.1158/1078-0432.CCR-13-1186. Epub 2013 Oct 4.

11.

Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.

Tan N, Wong M, Nannini MA, Hong R, Lee LB, Price S, Williams K, Savy PP, Yue P, Sampath D, Settleman J, Fairbrother WJ, Belmont LD.

Mol Cancer Ther. 2013 Jun;12(6):853-64. doi: 10.1158/1535-7163.MCT-12-0949. Epub 2013 Mar 8.

12.

GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.

Wallin JJ, Guan J, Prior WW, Lee LB, Berry L, Belmont LD, Koeppen H, Belvin M, Friedman LS, Sampath D.

Clin Cancer Res. 2012 Jul 15;18(14):3901-11. doi: 10.1158/1078-0432.CCR-11-2088. Epub 2012 May 14.

13.

Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.

Mérino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C, Yue P, Robati M, Phipson B, Fairlie WD, Lee EF, Campbell KJ, Vandenberg CJ, Cory S, Roberts AW, Ludlam MJ, Huang DC, Bouillet P.

Blood. 2012 Jun 14;119(24):5807-16. doi: 10.1182/blood-2011-12-400929. Epub 2012 Apr 26.

14.

Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.

Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ, Belmont LD.

Mol Cancer Ther. 2012 Apr;11(4):1026-35. doi: 10.1158/1535-7163.MCT-11-0693. Epub 2012 Feb 1.

15.

Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.

Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, Belmont LD, Kaminker JS, O'Rourke KM, Pujara K, Kohli PB, Johnson AR, Chiu ML, Lill JR, Jackson PK, Fairbrother WJ, Seshagiri S, Ludlam MJ, Leong KG, Dueber EC, Maecker H, Huang DC, Dixit VM.

Nature. 2011 Mar 3;471(7336):110-4. doi: 10.1038/nature09779. Erratum in: Nature. 2011 Jul 7;475(7354):122.

PMID:
21368834
16.

Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.

Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L, Fairbrother WJ, Sampath D, Belmont LD.

Clin Cancer Res. 2011 Mar 15;17(6):1394-404. doi: 10.1158/1078-0432.CCR-10-2353. Epub 2011 Jan 10.

17.

A chemosensitization screen identifies TP53RK, a kinase that restrains apoptosis after mitotic stress.

Peterson D, Lee J, Lei XC, Forrest WF, Davis DP, Jackson PK, Belmont LD.

Cancer Res. 2010 Aug 1;70(15):6325-35. doi: 10.1158/0008-5472.CAN-10-0015. Epub 2010 Jul 20.

18.

Antitumor activity of an allosteric inhibitor of centromere-associated protein-E.

Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR, Desai R, Schauer SP, McNulty DE, Annan RS, Belmont LD, Garcia C, Lee Y, Diamond MA, Faucette LF, Giardiniere M, Zhang S, Sun CM, Vidal JD, Lichtsteiner S, Cornwell WD, Greshock JD, Wooster RF, Finer JT, Copeland RA, Huang PS, Morgans DJ Jr, Dhanak D, Bergnes G, Sakowicz R, Jackson JR.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5839-44. doi: 10.1073/pnas.0915068107. Epub 2010 Feb 18.

19.

Actin structure function relationships revealed by yeast molecular genetics.

Belmont LD, Drubin DG.

Results Probl Cell Differ. 2001;32:103-21. Review. No abstract available.

PMID:
11131826
20.

In vivo importance of actin nucleotide exchange catalyzed by profilin.

Wolven AK, Belmont LD, Mahoney NM, Almo SC, Drubin DG.

J Cell Biol. 2000 Aug 21;150(4):895-904.

21.

New actin mutants allow further characterization of the nucleotide binding cleft and drug binding sites.

Belmont LD, Patterson GM, Drubin DG.

J Cell Sci. 1999 May;112 ( Pt 9):1325-36.

22.

A change in actin conformation associated with filament instability after Pi release.

Belmont LD, Orlova A, Drubin DG, Egelman EH.

Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):29-34.

23.

The yeast V159N actin mutant reveals roles for actin dynamics in vivo.

Belmont LD, Drubin DG.

J Cell Biol. 1998 Sep 7;142(5):1289-99.

25.

Real-time visualization of cell cycle-dependent changes in microtubule dynamics in cytoplasmic extracts.

Belmont LD, Hyman AA, Sawin KE, Mitchison TJ.

Cell. 1990 Aug 10;62(3):579-89.

PMID:
2379239

Supplemental Content

Loading ...
Support Center